For the second time, U.S. health regulators have denied approval for the use of Gardasil in women, ages 27 to 45. Officials want more long term clinical data. Merck’s Gardasil is said to protect against human papillomavirus (HPV), which can cause cervical cancer. Following the denial Merck’s shares dropped 79 cents. Merck is also pushing Gardasil for use among men; Reuters reports.